Shuttle Pharmaceuticals Announces $3.5 Million Public Offering
Rhea-AI Summary
Shuttle Pharmaceuticals (NASDAQ: SHPH) announced a public offering to issue 2,238,800 shares of common stock and pre-funded warrants to purchase 4,761,200 shares for aggregate gross proceeds of approximately $3.5 million.
The offering is expected to close on or about March 9, 2026, with E.F. Hutton & Co. as exclusive placement agent. The company intends to use up to $1.5 million for marketing and the remainder for working capital and general corporate purposes. The securities are being offered under an effective Form S-1 (File No. 333-293363) registration statement.
Positive
- Gross proceeds of approximately $3.5 million
- Up to $1.5 million earmarked for future marketing efforts
- Form S-1 registration effective on February 17, 2026
Negative
- Issuance of 2,238,800 shares plus pre-funded warrants for 4,761,200 shares may cause shareholder dilution
- Net proceeds reduced by placement agent fees and offering expenses
- Closing is subject to customary conditions and not certain (expected on March 9, 2026)
Key Figures
Market Reality Check
Peers on Argus
SHPH was down 6.27% while only one momentum peer (RDHL) showed an intraday move, rising about 3.64%. Other close peers showed mixed, mostly modest changes, pointing to a stock-specific reaction rather than a sector-wide move.
Previous Offering Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Oct 29 | Equity offering | Neutral | +0.0% | Announced $4.5M public offering to fund IND-enabling and Phase I/II trials. |
The prior tagged offering in October 2024 produced a 0% next-day move, suggesting historically muted immediate price response to capital raises.
Over the past 18 months, Shuttle Pharmaceuticals has repeatedly tapped the capital markets while pivoting its business model. A key prior event was the October 29, 2024 offering for $4.5 million, aimed at funding IND-enabling and Phase I/II trials, which saw a 0% 24-hour price reaction. More recently, private placements and Molecule.ai-related transactions expanded the share count and shifted focus toward AI-enabled discovery. Today’s $3.5 million public offering continues this pattern of equity financing, but proceeds are now directed mainly to marketing and general corporate purposes.
Historical Comparison
In the last year, SHPH reported one prior offering with an average 0% next-day move. Any pronounced reaction to this $3.5M raise would depart from that historically flat response.
Earlier offerings, like the $4.5M raise in October 2024, targeted clinical trial funding. The current $3.5M public offering shifts proceeds toward marketing and working capital, reflecting the transition from clinical programs toward promoting the AI-driven Molecule.ai platform and supporting general operations.
Market Pulse Summary
This announcement details a $3.5 million public offering involving 2,238,800 common shares and 4,761,200 pre-funded warrant shares, with up to $1.5 million earmarked for marketing and the balance for working capital. In context of a preliminary $10.9–$12.1 million 2025 net loss and a working capital deficit of $0.7–$0.8 million, the raise addresses liquidity but increases share count. Investors may watch future capital needs, Molecule.ai integration progress, and any shift in expense trends.
Key Terms
pre-funded warrants financial
securities purchase agreement financial
public offering financial
registration statement on form s-1 regulatory
prospectus regulatory
placement agent financial
AI-generated analysis. Not financial advice.
Gaithersburg, Maryland--(Newsfile Corp. - March 6, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), the owner of Molecule.ai, an artificial intelligence ("AI") driven platform for molecular discovery and early-stage drug development, today announced that it has entered into a securities purchase agreement with investors for the issuance and sale of 2,238,800 shares of common stock and pre-funded warrants to purchase 4,761,200 shares of common stock, in a public offering, for aggregate gross proceeds of approximately
E.F. Hutton & Co. is acting as the exclusive placement agent for the offering. The Company intends to use up to
The securities described above are being offered and sold by the Company in a public offering pursuant to a registration statement on Form S-1 (File No. 333-293363) that was originally filed with the Securities and Exchange Commission (the "SEC") on February 11, 2026, and became effective on February 17, 2026. The offering of the securities is being made only by means of a prospectus that forms a part of the effective registration statement. A preliminary prospectus relating to the offering has been filed with the SEC. A final prospectus relating to, and describing the terms of, the public offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Electronic copies of the final prospectus relating to the public offering, when available, may also be obtained by contacting E.F. Hutton & Co., at 745 Fifth Avenue, 34th Floor & PH, New York, NY 10151, by telephone at v, or by email at info@efhutton.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Shuttle Pharmaceuticals
Shuttle Pharma (NASDAQ: SHPH) owns a pharmaceutical software AI driven platform for molecular discovery and early-stage drug development. By combining modern AI techniques with structured scientific workflows, the Molecule.ai platform helps researchers explore the chemical space more efficiently, evaluate molecular ideas with greater clarity and make more informed decisions during the earliest stages of drug development.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include, but are not limited to, statements concerning the completion of the offering. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks related to our ability to satisfy the closing conditions related to the offering, general economic and market risks, and factors discussed in the "Risk Factors" section of Shuttle Pharma's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 26, 2025, as well as other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharma disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/286465
FAQ
What exactly is Shuttle Pharmaceuticals (SHPH) selling in the March 6, 2026 public offering?
When will the SHPH public offering close and who is the placement agent?
How does Shuttle Pharma plan to use the proceeds from the SHPH offering?
Are the SHPH securities being offered under an SEC registration statement?
Will the SHPH offering dilute existing shareholders and how certain is the closing?
